Preclinical data show that narazaciclib treatment led to significant tumor growth inhibition, demonstrating synergy with standard-of-care ibrutinib, in ibrutinib-sensitive and -resistant settings ...
Onconova Therapeutics™ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i™s
NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (œOnconova or œthe Company), a clinical-stage biopharmaceutical company focused on discovering and...
Showcase to feature presentations by key opinion leaders Drs. Gaël Roué and Bhavana Pothuri Showcase to take place on May 18, 2023 at 11:00 a.m. ET NEWTOWN, Pa., May 12, 2023 (GLOBE NEWSWIRE) --...
Onconova Therapeutics has dosed the first patient in its Phase I/IIa clinical trial of narazaciclib combined with letrozole to treat endometrial cancer.
Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion expected in 4Q 2023 NEWTOWN, Pa., May 11,...
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
NEWTOWN, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced plans for a Phase 1/2a trial of narazaciclib combined with letrozole in recurrent metastatic low-grade endometrioid endometrial cancer (LGEEC). In addition, the Company reported its third quarter 2022 financial results and provided a business update.
NEWTOWN, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for...